{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:31:21Z","timestamp":1777476681276,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Steroids affect bone health causing osteoporosis and fractures. The study aims to compare dual-release hydrocortisone (DR-HC) and conventional steroids on bone metabolism in patients with primary adrenal insufficiency (PAI). Thirty-five patients with PAI on conventional steroids (group A) and 35 patients switched to DR-HC (group B), consecutively referred at our hospital, were evaluated at baseline and after 18, 36 and 60\u00a0months of treatment. After 60\u00a0months of follow-up, patients in group A had a significant increase in body mass index (<jats:italic>p<\/jats:italic>\u2009=\u20090.004) and waist circumference (WC) (<jats:italic>p<\/jats:italic>\u2009=\u20090.026) and a significant decrease in osteocalcin (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), bone alkaline phosphatase (<jats:italic>p<\/jats:italic>\u2009=\u20090.029), lumbar spine bone mass density (BMD) T and Z scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and<jats:italic>p<\/jats:italic>\u2009=\u20090.001, respectively) and vertebral fractures rate (<jats:italic>p<\/jats:italic>\u2009=\u20090.021) than baseline. By contrast, patients in group B had a significant decrease in WC (<jats:italic>p<\/jats:italic>\u2009=\u20090.047) and increase in bone alkaline phosphatase (<jats:italic>p<\/jats:italic>\u2009=\u20090.019), lumbar spine BMD T score (<jats:italic>p<\/jats:italic>\u2009=\u20090.032), femoral neck BMD T and Z scores (<jats:italic>p<\/jats:italic>\u2009=\u20090.023 and<jats:italic>p<\/jats:italic>\u2009=\u20090.036, respectively) than baseline. Long-term conventional steroid replacement therapy is associated with a decrease in BMD, notably at lumbar spine, and increase in vertebral fractures rate. By contrast, DR-HC treatment is associated with improvement of BMD.<\/jats:p>","DOI":"10.1038\/s41598-022-13506-5","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T18:27:51Z","timestamp":1659464871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency"],"prefix":"10.1038","volume":"12","author":[{"given":"Valentina","family":"Guarnotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"13506_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong, P. & McCloskey, E. V. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat. Rev. Endocrinol. 16, 437\u2013447 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"13506_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","volume":"397","author":"ES Husebye","year":"2021","unstructured":"Husebye, E. S., Pearce, S. H., Krone, N. P. & K\u00e4mpe, O. Adrenal insufficiency. Lancet 397, 613\u2013629 (2021).","journal-title":"Lancet"},{"key":"13506_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12020-017-1501-4","volume":"59","author":"H Falhammar","year":"2018","unstructured":"Falhammar, H. Skeletal fragility induced by overtreatment of adrenal insufficiency. Endocrine 59, 239\u2013241 (2018).","journal-title":"Endocrine"},{"key":"13506_CR4","doi-asserted-by":"publisher","first-page":"e000014","DOI":"10.1136\/rmdopen-2014-000014","volume":"1","author":"K Briot","year":"2015","unstructured":"Briot, K. & Roux, C. Glucocorticoid-induced osteoporosis. RMD Open 1, e000014 (2015).","journal-title":"RMD Open"},{"key":"13506_CR5","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","volume":"379","author":"L Buckley","year":"2018","unstructured":"Buckley, L. & Humphrey, M. B. Glucocorticoid-Induced Osteoporosis. N. Engl. J. Med. 379, 2547\u20132556 (2018).","journal-title":"N. Engl. J. Med."},{"key":"13506_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000508321","volume":"26","author":"N Kiko","year":"2020","unstructured":"Kiko, N. & Kalhan, A. Comparison of various glucocorticoid replacement regimens used in chronic adrenal insufficiency: A systematic review. Dubai Diabetes Endocrinol. J. 26, 50\u201368 (2020).","journal-title":"Dubai Diabetes Endocrinol. J."},{"key":"13506_CR7","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Van Staa","year":"2003","unstructured":"Van Staa, T. P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Reum. 48, 3224\u20133229 (2003).","journal-title":"Arthritis Reum."},{"key":"13506_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12020-017-1512-1","volume":"60","author":"S Frara","year":"2018","unstructured":"Frara, S. et al. Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 60, 528\u2013531 (2018).","journal-title":"Endocrine"},{"key":"13506_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein, S. R. et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364\u2013389 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"13506_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","volume":"16","author":"JT Schousboe","year":"2013","unstructured":"Schousboe, J. T., Shepherd, J. A., Bilezikian, J. P. & Baim, S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J. Clin. Densitom. 16, 455\u2013466 (2013).","journal-title":"J. Clin. Densitom."},{"key":"13506_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coemr.2018.02.008","volume":"3","author":"G Bentivegna","year":"2018","unstructured":"Bentivegna, G., Osella, G., Pia, A. & Terzolo, M. Effects on bone health of glucocorticoid replacement therapy in primary and secondary adrenal insufficiency: A review. Curr. Opin. Endocrine Metab. Res. 3, 31\u201337 (2018).","journal-title":"Curr. Opin. Endocrine Metab. Res."},{"key":"13506_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","volume":"15","author":"M Steinbuch","year":"2004","unstructured":"Steinbuch, M., Youket, T. E. & Cohen, S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos. Int. 15, 323\u2013328 (2004).","journal-title":"Osteoporos. Int."},{"key":"13506_CR13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2265.2006.02473.x","volume":"64","author":"W Arlt","year":"2006","unstructured":"Arlt, W., Rosenthal, C., Hahner, S. & Allolio, B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin. Endocrinol. 64, 384\u2013389 (2006).","journal-title":"Clin. Endocrinol."},{"key":"13506_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1365-2265.2003.01761.x","volume":"58","author":"E J\u00f3dar","year":"2003","unstructured":"J\u00f3dar, E., Valdepe\u00f1as, M. P., Martinez, G., Jara, A. & Hawkins, F. Long term follow-up of bone mineral density in Addison\u2019s disease. Clin. Endocrinol. 58, 617\u2013620 (2003).","journal-title":"Clin. Endocrinol."},{"key":"13506_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/bmj.294.6575.798","volume":"294","author":"JP Devogelaer","year":"1994","unstructured":"Devogelaer, J. P., Crabb\u00e9, J. & Nagant de Deuxchaisnes, C. Bone mineral density in Addison\u2019s disease: evidence for an effect of adrenal androgens on bone mass. Br. Med. J. 294, 798\u2013800 (1994).","journal-title":"Br. Med. J."},{"key":"13506_CR16","first-page":"52","volume":"107","author":"CM Florkowski","year":"1994","unstructured":"Florkowski, C. M., Holmes, S. J., Elliot, J. R., Donald, R. A. & Espiner, E. A. Bone mineral density is reduced in female but not male subjects with Addison\u2019s disease. N. Z. Med. J. 107, 52\u201353 (1994).","journal-title":"N. Z. Med. J."},{"key":"13506_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-120-3-199402010-00005","volume":"120","author":"PM Zelissen","year":"1994","unstructured":"Zelissen, P. M., Croughs, R. J., Van Rijk, P. P. & Raymakers, J. A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. 120, 207\u2013210 (1994).","journal-title":"Ann. Intern. Med."},{"key":"13506_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s001980050251","volume":"10","author":"GD Braatvedt","year":"1999","unstructured":"Braatvedt, G. D., Joyce, M., Evans, M., Clearwater, J. & Reid, I. R. Bone mineral density in patients with treated Addison\u2019s disease. Osteoporos. Int. 10, 435\u2013440 (1999).","journal-title":"Osteoporos. Int."},{"key":"13506_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2011-2036","volume":"97","author":"KR Koetz","year":"2012","unstructured":"Koetz, K. R., Ventz, M., Diederich, S. & Quinkler, M. Bone mineral density is not significantly reduced in adult patients on low dose glucocorticoid replacement therapy. J. Clin. Endocrinol. Metabol. 97, 85\u201392 (2012).","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"13506_CR20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1530\/EJE-08-0880","volume":"160","author":"K L\u00f8v\u00e5s","year":"2009","unstructured":"L\u00f8v\u00e5s, K. et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone. Eur. J. Endocrinol. 160, 993\u20131002 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"13506_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-15-1096","volume":"174","author":"J Schulz","year":"2016","unstructured":"Schulz, J. et al. Reduction in daily HC dosage improves bone health in primary adrenal insufficiency. Eur. J. Endocrinol. 174, 531\u2013538 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"13506_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12020-010-9359-8","volume":"38","author":"L Leelarathna","year":"2010","unstructured":"Leelarathna, L. et al. Co-morbidities, management and clinical outcome of auto-immune Addison\u2019s disease. Endocrine 38, 113\u2013117 (2010).","journal-title":"Endocrine"},{"key":"13506_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11102-008-0126-2","volume":"11","author":"K Danilowicz","year":"2008","unstructured":"Danilowicz, K., Bruno, O. D., Manavela, M., Gomez, R. M. & Barkan, A. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 11, 279\u2013285 (2008).","journal-title":"Pituitary"},{"key":"13506_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1507\/endocrj.51.355","volume":"51","author":"N Chikada","year":"2004","unstructured":"Chikada, N., Imaki, T., Hotta, M., Sato, K. & Takano, K. An assessment of bone mineral density in patients with Addison\u2019s disease and isolated ACTH deficiency treated with glucocorticoid. Endocr. J. 51, 355\u2013360 (2004).","journal-title":"Endocr. J."},{"key":"13506_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4158\/EP151014.OR","volume":"22","author":"DD Chandy","year":"2016","unstructured":"Chandy, D. D. & Bhatia, E. Bone mineral density in patients with addison disease on replacement therapy with prednisolone. Endocr. Pract. 22, 434\u2013439 (2016).","journal-title":"Endocr. Pract."},{"key":"13506_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1365-2796.2011.02352.x","volume":"270","author":"S Bj\u00f6rnsdottir","year":"2011","unstructured":"Bj\u00f6rnsdottir, S. et al. Risk of hip fracture in Addison\u2019s disease: a population-based cohort study. J. Intern. Med. 270, 187\u2013195 (2011).","journal-title":"J. Intern. Med."},{"key":"13506_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12020-017-1380-8","volume":"59","author":"V Camozzi","year":"2017","unstructured":"Camozzi, V. et al. Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison\u2019s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine 59, 319\u2013329 (2017).","journal-title":"Endocrine"},{"key":"13506_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12020-021-02723-z","volume":"74","author":"L Li","year":"2021","unstructured":"Li, L., Bensing, S. & Falhammar, H. Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis. Endocrine 74, 29\u201337 (2021).","journal-title":"Endocrine"},{"key":"13506_CR29","doi-asserted-by":"crossref","unstructured":"Quinkler, M., Miodini, Nilsen, R., Zopf, K., Ventz, M., \u00d8ksnes, M. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619\u2013626 (2015).","DOI":"10.1530\/EJE-14-1114"},{"key":"13506_CR30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/cen.13554","volume":"88","author":"V Guarnotta","year":"2018","unstructured":"Guarnotta, V., Ciresi, A., Pillitteri, G. & Giordano, C. Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: A 36-month retrospective analysis. Clin. Endocrinol. 88, 665\u2013672 (2018).","journal-title":"Clin. Endocrinol."},{"key":"13506_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1530\/EC-19-0176","volume":"8","author":"V Guarnotta","year":"2019","unstructured":"Guarnotta, V. et al. Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8, 853\u2013862 (2019).","journal-title":"Endocr. Connect."},{"key":"13506_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","volume":"6","author":"AM Isidori","year":"2018","unstructured":"Isidori, A. M. et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173\u2013185 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"13506_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.coph.2021.07.003","volume":"60","author":"V Guarnotta","year":"2021","unstructured":"Guarnotta, V., Amodei, R. & Giordano, C. Metabolic comorbidities of adrenal insufficiency: Focus on steroid replacement therapy and chronopharmacology. Curr. Opin. Pharmacol. 60, 123\u2013132 (2021).","journal-title":"Curr. Opin. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13506-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13506-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13506-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T07:30:57Z","timestamp":1700897457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13506-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13506"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13506-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"10 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13280"}}